IMDX (Insight Molecular Diagnostics) Moat Score: 3/10 (As of Jun. 26, 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.65
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Moat Score?

Insight Molecular Diagnostics IMDX +1.25% 49 Moat Score is 3 as of Jun. 26, 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 76.96% on this metric.

Insight Molecular Diagnostics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Insight Molecular Diagnostics has No Moat: Insight Molecular Diagnostics Inc lacks significant market leadership or unique intellectual property. The company operates in a competitive industry with low switching costs and minimal brand strength, resulting in transient advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Insight Molecular Diagnostics might have No Moat - Very weak/transient advantages.

Insight Molecular Diagnostics  (NAS:IMDX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Insight Molecular Diagnostics Moat Score Related Terms

IMDX vs BDSX, XGN, FONR: Moat Score Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insight Molecular Diagnostics Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Moat Score distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Moat Score falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Insight Molecular Diagnostics (IMDX) has a Moat Score of 3 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Insight Molecular Diagnostics ranks #50 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 23%.
Is Insight Molecular Diagnostics' Moat Score too high?
Insight Molecular Diagnostics' current Moat Score is 3. Based on the distribution chart, Insight Molecular Diagnostics ranks #50 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Moat Score compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #50 out of 217 companies for Moat Score. This places Insight Molecular Diagnostics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Insight Molecular Diagnostics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.65 — trading 348.4% above its estimated fair value. The current Moat Score is 3. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Moat Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.65 is trading 348.4% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Moat Score: 3
  • GF Value™: $1.26 vs. price of $5.65 (348.4% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.65
Price
$1.26
GF Value